The enzyme RNA polymerase II transcribes genes into messenger RNA. This process is guided by modifications to the enzyme's ...

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western Hemisphere, affecting approximately ...

In the meta-analysis, the median follow-up ranged from 2 to 14 years and the median OS was between 10.1 and 12.7 months (where reported). Comparing patients with tumors NTRK+ and NTRK–, the pooled HR ...

Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With ROS1-Rearranged Advanced Lung Adenocarcinoma: A Multicenter, Retrospective Cohort Study A total of 33 patients with NTRK ...

Merck & Co (MSD) and Eisai are set to discontinue their Phase III clinical trial for unresectable, non‑metastatic ...

A myasthenia gravis treatment revolution has taken place in the past four years, spurred by an initial approval for argenx’s ...

Ianalumab targets the B-cell activating factor receptor (BAFR) and ibrutinib belongs to a class of therapeutics called Bruton ...

Merck & Co, known as MSD outside of the USA and Canada, and Japan’s Eisai today announced that the Phase III LITESPARK-011 ...

Hutchmed (HCM) “announces the completion of patient enrollment of SAFFRON, a global Phase III study of ORPATHYS and TAGRISSO for the treatment of ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; ...